MediciNova, Inc. (MNOV) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
Analysts estimate Earnings Per Share (EPS) of $-0.22 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.23 vs est $-0.22 (missed -4.5%). 2025: actual $-0.24 vs est $-0.38 (beat +36.8%). Analyst accuracy: 69%.
MNOV Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to MediciNova, Inc. in the past 3 months
EPS Estimates — MNOV
69%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.23
vs Est –$0.22
▼ 4.3% off
2025
Actual –$0.24
vs Est –$0.38
▲ 58.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — MNOV
37%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2025
Actual $0.000B
vs Est $0.000B
▲ 63.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
